chairman's message dear shareholders - Biosensors International ...

CHAIRMAN’S MESSAGE
DEAR SHAREHOLDERS,
FY 2011 (“FY11”) was another good year for Biosensors. Our
total revenue and net pro t both grew 35% over FY 2010
(“FY10”). The major contributor to such growth came from
our BioMatrix drug-eluting stents (“DES”). Our technology
continues to be validated both clinically and commercially.
As we demonstrate the safety and ef cacy of BioMatrix, we
continue to penetrate the DES market globally. As the DES
market continues to grow, the foundations we have built over
the past years will allow us to meet the challenges and grab
the opportunities in the future. Biosensors is prepared for very
exciting times ahead.
During FY11, we enhanced our shareholder
pro le with the entrance of Hony Capital.
In October 2010, Hony Capital made a
signi cant investment in Biosensors. Hony
– a leading global investment rm – will
prove to be an excellent partner to add
value to Biosensors’ future. Additionally,
we successfully completed a private
placement in March 2011. As a result, we
added two strategic shareholders, Atlantis
Investment Management (Hong Kong) and
Ever Union Capital, to our investor group.
This strengthened our balance sheet
to support our expansion plans. Hony’s
established reputation as a private equity
rm in Asia and its extensive knowledge of
the healthcare industry, together with the
investment expertise and experience of
04
BIOSENSORS INTERNATIONAL GROUP, LTD.

oth Atlantis Investment Management (Hong Kong) and Ever
Union Capital, bring immense strategic value to our company.
FY11 was also a year we strengthened our executive
management team. We appointed Dr. Jack Wang and Mr.
Jeffrey B. Jump as co-chief executive of cers. Both have
extensive medical device experience and have been working
for Biosensors for a long time. They are the rst internallypromoted
CEOs. Hence I am sure they will preserve and
protect the culture of Biosensors. They have also made
valuable contributions to the success of Biosensors over the
years. To complete the team, Mr. Ronald H. Ede joined us at
the beginning of scal year 2012 as our chief nancial of cer.
A veteran nancial manager with many years of healthcare
industry experience, Ronnie will support our business
strategies through his nancial, corporate management and
M&A experience. With the new team in place, we look forward
to Biosensors being led to greater heights.
I would like to thank each of you for your support and
con dence over the years that have brought Biosensors to
where we are today. As we move forward, with a strong new
base of investors and a strengthened management team,
I hope we can continue to count on your support over the
years ahead. I would also like to offer my sincere thanks to the
entire Biosensors team, whose collective efforts have helped
turn our vision into reality.
Meanwhile I will continue to work closely with our board
members and executive management team to develop
strategic initiatives. We will continue to look not only at internal
growth drivers such as new markets and products, but also at
external development opportunities.
Our business fundamentals remain excellent – and, have in
fact improved, thanks to our own internal development and
to the continued strong demand for medical devices in all the
markets we serve. We remain committed to our long-term
objective of becoming Asia’s leading DES company. We now
have a strong platform from which to realize this goal.
Sincerely,
Yoh-Chie LU
Chairman
ANNUAL REPORT 2010/11 05